Epigenetic alterations in colorectal cancer: The CpG island methylator phenotype

Histology and Histopathology

Volumn 28, Issue 5, 2013, Pages 585-595

  Jeong, Mo Bae ^a   Kim, Jung Ho ^a   Kang, Gyeong Hoon ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Colorectal cancers; CpG island methylator phenotype; DNA methylation; Epigenetics

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; DNA;

CELL TRANSFORMATION; COLORECTAL TUMOR; CPG ISLAND; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; HUMAN; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY; PROGNOSIS; REVIEW;

CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; EPIGENESIS, GENETIC; HUMANS; MUTATION; PHENOTYPE; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84877142499     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Ahn J.B., Chung W.B., Maeda O., Shin S.J., Kim H.S., Chung H.C., Kim N.K. and Issa J.P. (2011). DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer 117, 1847-1854.
2. Anacleto C., Leopoldino A.M., Rossi B., Soares F.A., Lopes A., Rocha J.C., Caballero O., Camargo A.A., Simpson A.J. and Pena S.D. (2005). Colorectal cancer methylator phenotype: fact or artifact? Neoplasia 7, 331-335.
3. Baba Y., Nosho K., Shima K., Freed E., Irahara N., Philips J., Meyerhardt J.A., Hornick J.L., Shivdasani R.A., Fuchs C.S. and Ogino S. (2009). Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin. Cancer Res. 15, 4665-4673.
4. Bae J.M., Kim M.J., Kim J.H., Koh J.M., Cho N.Y., Kim T.Y. and Kang G.H. (2011). Differential clinicopathological features in microsatellite instability-positive colorectal cancers depending on CIMP status. Virchows Arch. 459, 55-63.
5. Barault L., Charon-Barra C., Jooste V., de la Vega M.F., Martin L., Roignot P., Rat P., Bouvier A.M., Laurent-Puig P., Faivre J., Chapusot C. and Piard F. (2008). Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 68, 8541-8546.
6. Berman B.P., Weisenberger D.J., Aman J.F., Hinoue T., Ramjan Z., Liu Y., Noushmehr H., Lange C.P., van Dijk C.M., Tollenaar R.A., Van Den Berg D. and Laird P.W. (2012). Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat. Genet. 44, 40-46.
7. Bestor T.H. (2000). The DNA methyltransferases of mammals. Hum. Mol. Genet. 9, 2395-2402.
8. Bestor T.H. (2003). Unanswered questions about the role of promoter methylation in carcinogenesis. Ann. NY Acad. Sci. 983, 22-27.
9. Bird A. (2002). DNA methylation patterns and epigenetic memory. Genes Dev. 16, 6-21.
10. Boland C.R. and Goel A. (2010). Microsatellite instability in colorectal cancer. Gastroenterology 138, 2073-2087.
11. Bosman F.T., Carneiro F., Hruban R.H. and Theise N.D. (2010). WHO Classification of Tumours of the Digestive System. 4th ed. International Agency for Research on Cancer: Lyon.
12. Carragher L.A., Snell K.R., Giblett S.M., Aldridge V.S., Patel B., Cook S.J., Winton D.J., Marais R. and Pritchard C.A. (2010). V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Mol. Med. 2, 458-471.
13. Chirieac L.R., Shen L., Catalano P.J., Issa J.P. and Hamilton S.R. (2005). Phenotype of microsatellite-stable colorectal carcinomas with CpG island methylation. Am. J. Surg. Pathol. 29, 429-436.
14. Dahlin A.M., Palmqvist R., Henriksson M.L., Jacobsson M., Eklof V., Rutegard J., Oberg A. and Van Guelpen B.R. (2010). The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin. Cancer Res. 16, 1845-1855.
15. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., Marks K.M., Prins R.M., Ward P.S., Yen K.E., Liau L.M., Rabinowitz J.D., Cantley L.C., Thompson C.B., Vander Heiden M.G. and Su S.M. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739-744.
16. Day D.W. and Morson B.C. (1978). The adenoma-carcinoma sequence. Major Probl. Pathol. 10, 58-71.
17. De Carvalho D.D., You J.S. and Jones P.A. (2010). DNA methylation and cellular reprogramming. Trends Cell Biol. 20, 609-617.
18. Fearon E.R. and Vogelstein B. (1990). A genetic model for colorectal tumorigenesis. Cell 61, 759-767.
19. Feinberg A.P. and Vogelstein B. (1983). Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301, 89-92.
20. Gardiner-Garden M. and Frommer M. (1987). CpG islands in vertebrate genomes. J. Mol. Biol. 196, 261-282.
21. Goel A., Nagasaka T., Arnold C.N., Inoue T., Hamilton C., Niedzwiecki D., Compton C., Mayer R.J., Goldberg R., Bertagnolli M.M. and Boland C.R. (2007). The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 132, 127-138.
22. Goelz S.E., Vogelstein B., Hamilton S.R. and Feinberg A.P. (1985). Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 228, 187-190.
23. Hawkins N.J. and Ward R.L. (2001). Sporadic colorectal cancers with microsatellite instability and their possible origin in hyperplastic polyps and serrated adenomas. J. Natl. Cancer Inst. 93, 1307-1313.
24. Hawkins N., Norrie M., Cheong K., Mokany E., Ku S.L., Meagher A., O'Connor T. and Ward R. (2002). CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 122, 1376-1387.
25. Hinoue T., Weisenberger D.J., Pan F., Campan M., Kim M., Young J., Whitehall V.L., Leggett B.A. and Laird P.W. (2009). Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One 4, e8357.
26. Hinoue T., Weisenberger D.J., Lange C.P., Shen H., Byun H.M., Van Den Berg D., Malik S., Pan F., Noushmehr H., van Dijk C.M., Tollenaar R.A. and Laird P.W. (2012). Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 22, 271-282.
27. Hughes L.A., Khalid-de Bakker C.A., Smits K.M., van den Brandt P.A., Jonkers D., Ahuja N., Herman J.G., Weijenberg M.P. and van Engeland M. (2012). The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim. Biophys. Acta 1825, 77-85.
28. Issa J.P. (2004). CpG island methylator phenotype in cancer. Nat. Rev. Cancer 4, 988-993.
29. Jass J.R. (2002). Pathogenesis of colorectal cancer. Surg. Clin. North Am. 82, 891-904.
30. Jass J.R. (2007). Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50, 113-130.
31. Jass J.R. and Smith M. (1992). Sialic acid and epithelial differentiation in colorectal polyps and cancer-- a morphological, mucin and lectin histochemical study. Pathology 24, 233-242.
32. Jones P.A. and Baylin S.B. (2007). The epigenomics of cancer. Cell 128, 683-692.
33. Jover R., Nguyen T.P., Perez-Carbonell L., Zapater P., Paya A., Alenda C., Rojas E., Cubiella J., Balaguer F., Morillas J.D., Clofent J., Bujanda L., Rene J.M., Bessa X., Xicola R.M., Nicolas-Perez D., Castells A., Andreu M., Llor X., Boland C.R. and Goel A. (2011). 5- Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 140, 1174-1181.
34. Kang G.H. (2011). Four molecular subtypes of colorectal cancer and their precursor lesions. Arch. Pathol. Lab. Med. 135, 698-703.
35. Kim J.H., Shin S.H., Kwon H.J., Cho N.Y. and Kang G.H. (2009). Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch. 455, 485-494.
36. Kwon H.J., Kim J.H., Bae J.M., Cho N.Y., Kim T.Y. and Kang G.H. (2010). DNA methylation changes in ex-adenoma carcinoma of the large intestine. Virchows Arch. 457, 433-441.
37. Laird P.W. (2005). Cancer epigenetics. Hum. Mol. Genet. 14 Spec No 1, R65-R76.
38. Lee S., Cho N.Y., Choi M., Yoo E.J., Kim J.H. and Kang G.H. (2008a). Clinicopathological features of CpG island methylator phenotype- positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol. Int. 58, 104-113.
39. Lee S., Cho N.Y., Yoo E.J., Kim J.H. and Kang G.H. (2008b). CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. Arch. Pathol. Lab. Med. 132, 1657-1665.
40. Lugli A., Tzankov A., Zlobec I. and Terracciano L.M. (2008). Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status. Mod. Pathol. 21, 1403-1412.
41. McGregor D.K., Wu T.T., Rashid A., Luthra R. and Hamilton S.R. (2004). Reduced expression of cytokeratin 20 in colorectal carcinomas with high levels of microsatellite instability. Am. J. Surg. Pathol. 28, 712-718.
42. Meissner A. (2010). Epigenetic modifications in pluripotent and differentiated cells. Nat. Biotechnol. 28, 1079-1088.
43. Min B.H., Bae J.M., Lee E.J., Yu H.S., Kim Y.H., Chang D.K., Kim H.C., Park C.K., Lee S.H., Kim K.M. and Kang G.H. (2011). The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine- based adjuvant chemotherapy. BMC Cancer 11, 344.
44. Morson B.C. (1962). Precancerous lesions of the colon and rectum. Classification and controversial issues. JAMA 179, 316-321.
45. Nagasaka T., Koi M., Kloor M., Gebert J., Vilkin A., Nishida N., Shin S.K., Sasamoto H., Tanaka N., Matsubara N., Boland C.R. and Goel A. (2008). Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology 134, 1950-1960, 1960 e1951.
46. O'Brien M.J., Yang S., Mack C., Xu H., Huang C.S., Mulcahy E., Amorosino M. and Farraye F.A. (2006). Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am. J. Surg. Pathol. 30, 1491-1501.
47. Ogino S. and Goel A. (2008). Molecular classification and correlates in colorectal cancer. J. Mol. Diagn. 10, 13-27.
48. Ogino S., Cantor M., Kawasaki T., Brahmandam M., Kirkner G.J., Weisenberger D.J., Campan M., Laird P.W., Loda M. and Fuchs S. (2006). CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 55, 1000-1006.
49. Ogino S., Kawasaki T., Kirkner G.J., Loda M. and Fuchs C.S. (2006b). CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J. Mol. Diagn. 8, 582-588.
50. Ogino S., Odze R.D., Kawasaki T., Brahmandam M., Kirkner G.J., Laird P.W., Loda M. and Fuchs C.S. (2006c). Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Am. J. Surg. Pathol. 30, 1175-1183.
51. Ogino S., Kawasaki T., Kirkner G.J., Kraft P., Loda M. and Fuchs C.S. (2007a). Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J. Mol. Diagn. 9, 305-314.
52. Ogino S., Meyerhardt J.A., Kawasaki T., Clark J.W., Ryan D.P., Kulke M.H., Enzinger P.C., Wolpin B.M., Loda M. and Fuchs C.S. (2007b). CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 450, 529-537.
53. Ogino S., Nosho K., Kirkner G.J., Kawasaki T., Meyerhardt J.A., Loda M., Giovannucci E.L. and Fuchs C.S. (2009). CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58, 90-96.
54. Pancione M., Di Blasi A., Sabatino L., Fucci A., Dalena A.M., Palombi N., Carotenuto P., Aquino G., Daniele B., Normanno N. and Colantuoni V. (2011). A novel case of rhabdoid colon carcinoma associated with a positive CpG island methylator phenotype and BRAF mutation. Hum. Pathol. 42, 1047-1052.
55. Park S.Y., Kim B.H., Kim J.H., Lee S. and Kang G.H. (2007). Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch. Pathol. Lab. Med. 131, 1561-1567.
56. Portela A. and Esteller M. (2010). Epigenetic modifications and human disease. Nat. Biotechnol. 28, 1057-1068.
57. Rozek L.S., Lipkin S.M., Fearon E.R., Hanash S., Giordano T.J., Greenson J.K., Kuick R., Misek D.E., Taylor J.M., Douglas J.A., Rennert G. and Gruber S.B. (2005). CDX2 polymorphisms, RNA expression, and risk of colorectal cancer. Cancer Res. 65, 5488-5492.
58. Samowitz W.S., Albertsen H., Herrick J., Levin T.R., Sweeney C., Murtaugh M.A., Wolff R.K. and Slattery M.L. (2005). Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 129, 837-845.
59. Sanchez J.A., Krumroy L., Plummer S., Aung P., Merkulova A., Skacel M., DeJulius K.L., Manilich E., Church J.M., Casey G. and Kalady M.F. (2009). Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. Br. J. Surg. 96, 1196-1204.
60. Saxonov S., Berg P. and Brutlag D.L. (2006). A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc. Natl. Acad. Sci. USA 103, 1412-1417.
61. Shen L., Toyota M., Kondo Y., Lin E., Zhang L., Guo Y., Hernandez N.S., Chen X., Ahmed S., Konishi K., Hamilton S.R. and Issa J.P. (2007a). Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl. Acad. Sci. USA 104, 18654-18659.
62. Shen L., Catalano P.J., Benson A.B. 3rd, O'Dwyer P., Hamilton S.R. and Issa J.P. (2007b). Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin. Cancer Res. 13, 6093-6098.
63. Shen L., Kondo Y., Ahmed S., Boumber Y., Konishi K., Guo Y., Chen X., Vilaythong J.N. and Issa J.P. (2007c). Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Res. 67, 11335-11343.
64. Silverman A.L., Park J.G., Hamilton S.R., Gazdar A.F., Luk G.D. and Baylin S.B. (1989). Abnormal methylation of the calcitonin gene in human colonic neoplasms. Cancer Res. 49, 3468-3473.
65. Takai D. and Jones P.A. (2002). Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl. Acad. Sci. USA 99, 3740-3745.
66. Toyota M., Ahuja N., Ohe-Toyota M., Herman J.G., Baylin S.B. and Issa J.P. (1999). CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. USA 96, 8681-8686.
67. Tuppurainen K., Makinen J.M., Junttila O., Liakka A., Kyllonen A.P., Tuominen H., Karttunen T.J. and Makinen M.J. (2005). Morphology and microsatellite instability in sporadic serrated and non-serrated colorectal cancer. J. Pathol. 207, 285-294.
68. Turcan S., Rohle D., Goenka A., Walsh L.A., Fang F., Yilmaz E., Campos C., Fabius A.W., Lu C., Ward P.S., Thompson C.B., Kaufman A., Guryanova O., Levine R., Heguy A., Viale A., Morris L.G., Huse J.T., Mellinghoff I.K. and Chan T.A. (2012). IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 479-483.
69. Van Rijnsoever M., Grieu F., Elsaleh H., Joseph D. and Iacopetta B. (2002). Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 51, 797-802.
70. Van Rijnsoever M., Elsaleh H., Joseph D., McCaul K. and Iacopetta B. (2003). CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin. Cancer Res. 9, 2898-2903.
71. Vaughn C.P., Wilson A.R. and Samowitz W.S. (2010). Quantitative evaluation of CpG island methylation in hyperplastic polyps. Mod. Pathol. 23, 151-156.
72. Ward R.L., Cheong K., Ku S.L., Meagher A., O'Connor T. and Hawkins N.J. (2003). Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J. Clin. Oncol. 21, 3729-3736.
73. Weisenberger D.J., Siegmund K.D., Campan M., Young J., Long T.I., Faasse M.A., Kang G.H., Widschwendter M., Weener D., Buchanan, Koh H., Simms L., Barker M., Leggett B., Levine J., Kim M., French A.J., Thibodeau S.N., Jass J., Haile R. and Laird P.W. (2006). CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 38, 787-793.
74. Wynter C.V., Walsh M.D., Higuchi T., Leggett B.A., Young J. and Jass J.R. (2004). Methylation patterns define two types of hyperplastic polyp associated with colorectal cancer. Gut 53, 573-580.
75. Xu Y., Hu B., Choi A.J., Gopalan B., Lee B.H., Kalady M.F., Church J.M. and Ting A.H. (2012). Unique DNA methylome profiles in CpG island methylator phenotype colon cancers. Genome Res. 22, 283-291.
76. Yagi K., Akagi K., Hayashi H., Nagae G., Tsuji S., Isagawa T., Midorikawa Y., Nishimura Y., Sakamoto H., Seto Y., Aburatani H. and Kaneda A. (2010). Three DNA methylation epigenotypes in human colorectal cancer. Clin. Cancer Res. 16, 21-33.
77. Yamashita K., Dai T., Dai Y., Yamamoto F. and Perucho M. (2003). Genetics supersedes epigenetics in colon cancer phenotype. Cancer Cell 4, 121-131.
78. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G.J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K.W., Velculescu V.E., Vogelstein B. and Bigner D.D. (2009). IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773.
79. Yang S., Farraye F.A., Mack C., Posnik O. and O'Brien M.J. (2004). BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am. J. Surg. Pathol. 28, 1452-1459.
80. Zhao S., Lin Y., Xu W., Jiang W., Zha Z., Wang P., Yu W., Li Z., Gong L., Peng Y., Ding J., Lei Q., Guan K.L. and Xiong Y. (2009). Glioma- derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324, 261-265.
81. Zlobec I., Bihl M., Foerster A., Rufle A. and Lugli A. (2011). Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. J. Pathol. 225, 336-343.